Logo image of FHTX

FOGHORN THERAPEUTICS INC (FHTX) Stock Fundamental Analysis

NASDAQ:FHTX - Nasdaq - US3441741077 - Common Stock - Currency: USD

3.88  -0.36 (-8.49%)

After market: 3.88 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FHTX. FHTX was compared to 563 industry peers in the Biotechnology industry. FHTX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, FHTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FHTX has reported negative net income.
In the past year FHTX has reported a negative cash flow from operations.
FHTX had negative earnings in each of the past 5 years.
FHTX had negative operating cash flow in 4 of the past 5 years.
FHTX Yearly Net Income VS EBIT VS OCF VS FCFFHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.50%, FHTX is in the better half of the industry, outperforming 66.07% of the companies in the same industry.
Industry RankSector Rank
ROA -30.5%
ROE N/A
ROIC N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FHTX Yearly ROA, ROE, ROICFHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

1.3 Margins

FHTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FHTX Yearly Profit, Operating, Gross MarginsFHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FHTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FHTX has more shares outstanding
FHTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FHTX Yearly Shares OutstandingFHTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
FHTX Yearly Total Debt VS Total AssetsFHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

FHTX has an Altman-Z score of -2.64. This is a bad value and indicates that FHTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.64, FHTX perfoms like the industry average, outperforming 50.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.64
ROIC/WACCN/A
WACC10.09%
FHTX Yearly LT Debt VS Equity VS FCFFHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

FHTX has a Current Ratio of 3.73. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.73, FHTX perfoms like the industry average, outperforming 44.23% of the companies in the same industry.
A Quick Ratio of 3.73 indicates that FHTX has no problem at all paying its short term obligations.
FHTX has a Quick ratio (3.73) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.73
Quick Ratio 3.73
FHTX Yearly Current Assets VS Current LiabilitesFHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.49% over the past year.
Looking at the last year, FHTX shows a very negative growth in Revenue. The Revenue has decreased by -33.83% in the last year.
The Revenue has been growing by 157.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)29.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.37%
Revenue 1Y (TTM)-33.83%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%-50.49%

3.2 Future

The Earnings Per Share is expected to grow by 14.78% on average over the next years. This is quite good.
FHTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.86% yearly.
EPS Next Y16.3%
EPS Next 2Y15.99%
EPS Next 3Y4.03%
EPS Next 5Y14.78%
Revenue Next Year-16.76%
Revenue Next 2Y1.21%
Revenue Next 3Y11.06%
Revenue Next 5Y24.86%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FHTX Yearly Revenue VS EstimatesFHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
FHTX Yearly EPS VS EstimatesFHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FHTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FHTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FHTX Price Earnings VS Forward Price EarningsFHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FHTX Per share dataFHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.99%
EPS Next 3Y4.03%

More info and screens

0

5. Dividend

5.1 Amount

FHTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FOGHORN THERAPEUTICS INC

NASDAQ:FHTX (5/5/2025, 8:09:25 PM)

After market: 3.88 0 (0%)

3.88

-0.36 (-8.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners73.07%
Inst Owner Change-0.05%
Ins Owners8.04%
Ins Owner Change0%
Market Cap215.77M
Analysts82.86
Price Target11.37 (193.04%)
Short Float %2.37%
Short Ratio8.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.54%
Min EPS beat(2)10.09%
Max EPS beat(2)30.99%
EPS beat(4)4
Avg EPS beat(4)20.61%
Min EPS beat(4)8.69%
Max EPS beat(4)32.64%
EPS beat(8)8
Avg EPS beat(8)21.58%
EPS beat(12)9
Avg EPS beat(12)11.17%
EPS beat(16)11
Avg EPS beat(16)5.37%
Revenue beat(2)1
Avg Revenue beat(2)-20.53%
Min Revenue beat(2)-61.83%
Max Revenue beat(2)20.77%
Revenue beat(4)2
Avg Revenue beat(4)-14.41%
Min Revenue beat(4)-61.83%
Max Revenue beat(4)20.77%
Revenue beat(8)5
Avg Revenue beat(8)29.35%
Revenue beat(12)5
Avg Revenue beat(12)4.16%
Revenue beat(16)8
Avg Revenue beat(16)23.89%
PT rev (1m)-3.11%
PT rev (3m)-7.14%
EPS NQ rev (1m)1.11%
EPS NQ rev (3m)8.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.93%
Revenue NQ rev (1m)-2.74%
Revenue NQ rev (3m)6.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.55
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.81
OCFYN/A
SpS0.41
BVpS-0.82
TBVpS-0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.04%
Cap/Sales 4.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.73
Quick Ratio 3.73
Altman-Z -2.64
F-Score2
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)33.62%
Cap/Depr(5y)290.03%
Cap/Sales(3y)4.61%
Cap/Sales(5y)806.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.37%
EPS Next Y16.3%
EPS Next 2Y15.99%
EPS Next 3Y4.03%
EPS Next 5Y14.78%
Revenue 1Y (TTM)-33.83%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%-50.49%
Revenue Next Year-16.76%
Revenue Next 2Y1.21%
Revenue Next 3Y11.06%
Revenue Next 5Y24.86%
EBIT growth 1Y7.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.09%
EBIT Next 3Y-2.81%
EBIT Next 5YN/A
FCF growth 1Y15.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.99%
OCF growth 3YN/A
OCF growth 5YN/A